Control Group:Secukinumab

2 trials

Sponsors

Beijing Luhe Hospital, Capital Medical University, China-Japan Friendship Hospital

Conditions

Moderate to severe plaque psoriasispsoriasis

Phase 4

Clinical Study on Secukinumab combined with Apremilast in the treatment of moderate-to-severe Plaque Psoriasis

Active, not recruitingChiCTR2600116913

Beijing Luhe Hospital, Capital Medical UniversityModerate to severe plaque psoriasis

Start: 2026-01-20Updated: 2026-01-27

Unknown Phase

A Clinical Study of Huoxue Xiaoyin Decoction Combined with Xueluo Triple Therapy in the Treatment of Psoriasis

Active, not recruitingITMCTR2026000987

China-Japan Friendship Hospitalpsoriasis

Start: 2023-12-01Updated: 2026-04-28